PL1814595T3 - Leczenie raka za pomocą kombinacji czynnika zakłócającego ścieżkę sygnalizacyjną EGF oraz oligonukleotydu obniżającego poziom klusteryny - Google Patents

Leczenie raka za pomocą kombinacji czynnika zakłócającego ścieżkę sygnalizacyjną EGF oraz oligonukleotydu obniżającego poziom klusteryny

Info

Publication number
PL1814595T3
PL1814595T3 PL05810600T PL05810600T PL1814595T3 PL 1814595 T3 PL1814595 T3 PL 1814595T3 PL 05810600 T PL05810600 T PL 05810600T PL 05810600 T PL05810600 T PL 05810600T PL 1814595 T3 PL1814595 T3 PL 1814595T3
Authority
PL
Poland
Prior art keywords
perturbs
oligonucleotide
cancer
agent
treatment
Prior art date
Application number
PL05810600T
Other languages
English (en)
Polish (pl)
Inventor
Martin Gleave
Gabriella Zupi
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of PL1814595T3 publication Critical patent/PL1814595T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL05810600T 2004-11-23 2005-11-22 Leczenie raka za pomocą kombinacji czynnika zakłócającego ścieżkę sygnalizacyjną EGF oraz oligonukleotydu obniżającego poziom klusteryny PL1814595T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52294804P 2004-11-23 2004-11-23
US52296004P 2004-11-24 2004-11-24
PCT/CA2005/001775 WO2006056054A1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
EP05810600.6A EP1814595B1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels

Publications (1)

Publication Number Publication Date
PL1814595T3 true PL1814595T3 (pl) 2014-08-29

Family

ID=36497699

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05810600T PL1814595T3 (pl) 2004-11-23 2005-11-22 Leczenie raka za pomocą kombinacji czynnika zakłócającego ścieżkę sygnalizacyjną EGF oraz oligonukleotydu obniżającego poziom klusteryny

Country Status (11)

Country Link
US (2) US20080014198A1 (cg-RX-API-DMAC10.html)
EP (1) EP1814595B1 (cg-RX-API-DMAC10.html)
JP (1) JP4980919B2 (cg-RX-API-DMAC10.html)
AU (1) AU2005309274B2 (cg-RX-API-DMAC10.html)
CA (1) CA2584646C (cg-RX-API-DMAC10.html)
DK (1) DK1814595T3 (cg-RX-API-DMAC10.html)
ES (1) ES2456017T3 (cg-RX-API-DMAC10.html)
PL (1) PL1814595T3 (cg-RX-API-DMAC10.html)
PT (1) PT1814595E (cg-RX-API-DMAC10.html)
SI (1) SI1814595T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006056054A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
RU2013145869A (ru) 2011-03-15 2015-04-20 Дзе Юниверсити Оф Бритиш Коламбиа КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
MD20140101A2 (ro) * 2013-02-22 2015-02-28 Alethia Biotherapeutics Inc. Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DK0882061T3 (da) * 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
NZ513757A (en) * 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
AU2003237790A1 (en) * 2002-05-14 2003-12-02 Baylor College Of Medicine Small molecule inhibitors of her2 expression
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
CA2520518A1 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Also Published As

Publication number Publication date
AU2005309274B2 (en) 2011-07-21
EP1814595A4 (en) 2009-04-15
JP4980919B2 (ja) 2012-07-18
DK1814595T3 (da) 2014-03-31
EP1814595B1 (en) 2014-01-08
US20080014198A1 (en) 2008-01-17
CA2584646A1 (en) 2006-06-01
US20110142827A1 (en) 2011-06-16
WO2006056054A1 (en) 2006-06-01
EP1814595A1 (en) 2007-08-08
PT1814595E (pt) 2014-04-02
JP2008520591A (ja) 2008-06-19
ES2456017T3 (es) 2014-04-21
CA2584646C (en) 2015-11-03
SI1814595T1 (sl) 2014-06-30
AU2005309274A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
IL185679A0 (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
IL187898A0 (en) Parp modulators and treatment of cancer
ZA200803048B (en) Microangiopathy treatment and prevention
IL186662A0 (en) Combination cancer therapy with
EP1727498A4 (en) DEVICES AND METHODS FOR ENDOVASCULAR TREATMENT
PL1974579T3 (pl) Zlokalizowana i rozproszona transmisja
ZA200903173B (en) Cancer susceptibility variants on chr8q24.21
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
IL182533A0 (en) Prostate treatment stent
EP2022512A4 (en) CATHETER HOSE AND CATHETER WITH HOSE
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
PL2010191T3 (pl) Leczenie przeciwrakowe skojarzeniem paklitakselu i 13- deoksyantracyklin
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
IL192144A0 (en) Combination comprising combretastatin and anticancer agents
GB0428180D0 (en) Combination therapy
SI1814595T1 (sl) Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
PL1806134T3 (pl) Środek i produkt żywnościowy do zapobiegania/leczenia czynnościowych zaburzeń trawiennych
GB0424339D0 (en) Combination therapy
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0428187D0 (en) Cancer treatment
ZA200610032B (en) Oculoselective drugs and prodrugs
GB0607949D0 (en) Mono and combination therapy
GB0413346D0 (en) Treating cancer
GB0428170D0 (en) Mono and Combination Therapy